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Abstract. A novel hydrophobic chitosan derivative, octanoyl chitosan (OC) with 
improved organic solubility was synthesized, characterized, and employed for the preparation 
of rifampicin (Rif) encapsulated nanoparticle formulations for pulmonary delivery. OC was 
characterized to conﬁrm acyl group substitution and cytotoxicity in A549 epithelial lung cells. 
OC nanoparticles were produced by the double emulsion solvent evaporation technique 
without cross-linking and characterized for particle size distribution, morphology, crystallin- 
ity, thermal stability, aerosol delivery, and drug release rate. OC was successfully synthesized 
with substitution degree of 44.05 ± 1.75%, and solubility in a range of organic solvents. 
Preliminary cytotoxicity studies of OC showed no effect on cell viability over a period of 24 h 
on A549 cell lines. OC nanoparticles were optimized using a 32 full factorial design. An 
optimized batch of OC nanoparticles, smooth and spherical in morphology, had mean 
hydrodynamic diameter of 253 ± 19.06 nm (PDI 0.323 ± 0.059) and entrapment efﬁciency of 
64.86 ± 7.73% for rifampicin. Pulmonary deposition studies in a two-stage impinger following 
aerosolization of nanoparticles from a jet nebulizer gave a ﬁne particle fraction of 43.27 ± 
4.24%. In vitro release studies indicated sustained release (73.14 ± 3.17%) of rifampicin from 
OC nanoparticles over 72 h, with particles demonstrating physical stability over 2 months. In 
summary, the results conﬁrmed the suitability of the developed systems for pulmonary 
delivery of drugs with excellent aerosolization properties and sustained-release 
characteristics. 
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INTRODUCTION 
 
Being the second leading cause of death worldwide from 
infectious diseases, after the human immunodeﬁciency virus 
(HIV) (1), tuberculosis (TB) is continuously posing a major 
global health problem. The latest estimate by the World  
Health Organization (WHO) indicated 10.4 million new cases 
of TB in 2016, of which 6.8 and 1.5 million cases, 
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corresponding to 65 and 15%, were among men and women 
respectively, while 1.0 million (10%) were among children. 
People having co-infection of HIV with TB were calculated to 
be 1.2 million (10%) of all new TB cases, while drug-resistant 
TB is a continued threat (1). Currently, chemotherapy is the 
only available option for the treatment of TB. However, it has 
several limitations such as lengthy treatment (requiring 
combination antibiotics therapy daily for 6–9 months), patient 
non-compliance, non-localized delivery, worsening of the 
disease due to co-infection with HIV and generation of drug-
resistant mutants of TB bacilli. Moreover, high dose, dosing 
frequency, and adverse side effects are other major factors 
limiting the effectiveness of the current TB chemo- therapy 
(2). Among several  anti-TB  drugs,  rifampicin  (RIF) is one of 
the most effective and is an important component of DOTS 
(directly observed treatment, short-course) therapy. It is 
considered a model anti-TB drug, with well-deﬁned chemical 
and physical properties. However, a series of limitations such 
as low bioavailability, enhanced drug resis- tance, less cell 
permeability, inability to achieve adequate drug 
concentrations at the infected site, and degradation before 
reaching the target site have impeded its effectiveness 
 
 
 
  
(2). Therefore, developing an alternative delivery system and 
route of administration for rifampicin would clearly be 
advantageous. 
The inhaled route of administration is receiving increas- 
ing attention for direct and target speciﬁc delivery of drug to 
the lungs due to the large alveolar surface area, extensive 
vascularization, limited proteolytic activity, avoidance of ﬁrst- 
pass metabolism, and rapid onset of drug action (3). However, 
lack of retention of drugs in the lungs and some invasive 
procedures for drug administration have hindered its clinical 
application (2). Sustained and targeted drug delivery to the 
pulmonary site is usually achieved by formulating drugs in 
micro- or nanoparticle structures, which can be adminis- 
tered as a therapeutic aerosol. Formulation of anti-TB drug 
into nanoparticulate carrier system for pulmonary delivery 
could help to solve these issues associated with their current 
use. The small-sized colloidal nanoparticles have easy pene- 
tration into the alveoli, may have enhanced alveolar macro- 
phage uptake compared to microparticles and can achieve an 
effective therapeutic outcome (4,5). 
Several polymers have been employed for the preparation 
of nanoparticles for pulmonary delivery including, polylactic-co- 
glycolic acid, polycaprolactone, chitosan, and alginates. (6,7) 
Chitosan, a natural polymer, consisting mainly of β (1 → 4)- 
linked D-glucosamine and N-acetyl β-D-glucosamine, has been 
widely used owing to its advantages such as biodegradability, 
biocompatibility, mucoadhesive property (due to positive 
charge in aqueous environments), low toxicity, and antimicro- 
bial activity (8). Moreover, improved entrapment and uptake by 
the alveolar macrophages for effective targeting has made this 
polymer a choice for the lung delivery (4). There are reports 
demonstrating application of chitosan microparticles and nano- 
particles for delivery of drugs and macromolecules to the lung 
(9–12). However, loss of their positive surface charge, aggregate 
formation at physiologic pH, and their inability to protect and 
control the release of small molecular drugs have contributed to 
chitosan’s current limited applications in drug delivery (13,14). 
Various chemical modiﬁcations of chitosan have been investi- 
gated in order to overcome these limitations by conjugating 
hydrophobic and hydrophilic groups (owing to the presence of 
reactive amine and hydroxyl groups) for application in 
drug/protein delivery (12,15). Modiﬁcation of chitosan by 
acylation (using acyl chlorides and anhydrides) confers organic 
solubility and an ester linkage is hydrolyzable by enzymes such 
as lipase (13). Several methods for synthesizing hydrophobic 
chitosan derivatives for biomedical applications have been 
reported (12,16–18), while nanoparticles were produced mainly 
by cross-linking, drying, reverse micellar, or emulsion cross- 
linking. The cross-linking method often involves the use of 
potential toxic agents such as glutaraldehyde, making this 
methodology less effective and tedious due to post-formulation 
removal of cross-linking agents. To the best of our knowledge, 
there have been no reports exploring hydrophobic chitosan 
derivative (OC) for the preparation of nanoparticles by 
emulsiﬁcation without cross-linking. 
Thus, the present study describes the utilization of hydro- 
phobic chitosan in the preparation of nanoparticles for pulmo- 
nary delivery of rifampicin using an emulsion solvent 
evaporation technique without cross-linking. The aim of the 
study was to produce suitably sized rifampicin-loaded octanoyl 
chitosan nanoparticles using a freeze-drying process, while 
optimization of the formula was achieved by factorial design. 
MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bro- 
mide) assay indicated the suitability of the presented polymer for 
safe use in drug delivery. The physicochemical properties, 
loading capacity (LC), encapsulation efﬁciency (EE), and release 
properties of encapsulated rifampicin were investigated, while 
stability studies indicated the stability of the octanoyl chitosan 
nanoparticles. In sum, this study clearly demonstrated positively 
charged nanoparticles with a release-controlling ability of 
octanoyl chitosan, suggesting its suitability as a novel drug carrier 
for pulmonary delivery. 
 
MATERIALS AND METHODS 
 
Materials 
 
Rifampicin was purchased from Sigma-Aldrich (St. 
Louis, USA). Chitosan oligosaccharide [MW > 5 kDa; degree 
of deacetylation (DDA) 80–90%] was supplied by Kitto Life 
Co. Ltd. (Kyongki-Do, Seoul, South Korea). Octanoyl 
chloride, methane sulfonic acid, sodium bicarbonate, 
Poloxamer F-127, and polyvinyl alcohol (PVA) were pur- 
chased from Sigma-Aldrich (St. Louis, USA). Cellulose 
dialysis tubing (Molecular weight cut-off 12–14,000 Da and 
5000 Da) was purchased from Medicell International Ltd., 
(London, UK). Dimethyl sulfoxide (DMSO, anhydrous), 
methanol, ethanol, chloroform, dichloromethane (DCM), 
acetone and all other HPLC grade solvents were obtained 
from Sigma-Aldrich (St. Louis, USA). 
 
Methods 
 
Preparation of OC and OC-Rif Nanoparticles 
 
Octanoyl chitosan was synthesized as per the method 
described by Huang et al. with modiﬁcations and conﬁrmed 
using NMR and FTIR studies (14). The ﬁnal product was 
further utilized to prepare nanoparticles (see supporting 
information). 
OC nanoparticles were prepared using the double 
emulsion solvent evaporation technique as previously de- 
scribed (19). Accurately weighed (50 mg) OC was dissolved   
in 1.5 ml of dichloromethane. The required quantity of 
rifampicin (5–15 mg) was dissolved in this solution with 
agitation until complete dissolution. Organic phase was 
emulsiﬁed immediately with aqueous phase  by  sonication  
for 15 s at 15 Amp to form a primary emulsion. The emulsion 
obtained was then poured into 10 ml of aqueous phase 
containing 0.5%  PVA  (polyvinyl  alcohol)  and  sonicated  at  
15 Amp for 30 s (Labsonic® P, Sartorius Biotech GmbH, 
Germany). The resultant multiple emulsion was magnetically 
stirred (RO 10 power IKA WERKE, Staufen, Germany) at  25–
30 °C for about 4 h to completely evaporate the organic phase. 
Recovery of nanoparticles formed was achieved by 
centrifugation at 21000 rpm for 30 min (Sigma Laboratory 
Centrifuge, 3K30, UK). Samples were washed three  times  
with fresh deionized water to remove any residual surfactant 
(PVA) and free drug. Nanoparticles obtained were then 
lyophilized (VirTis Co. Inc., UK) following addition of 
cryoprotectant, trehalose dehydrate (1% w/v) as described 
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by Holzer et al., (20). A similar protocol was followed to 
prepare blank OC NPs without rifampicin. 
 
Optimization of Particle Size and Entrapment Efficiency by 
Factorial Design 
 
Preliminary optimization was carried out to study the 
inﬂuence of process parameters such as sonication time, 
organic solvent, surfactant, and concentration of surfactant. 
Thereafter, blank OC NPs and rifampicin-loaded OC NPs (OC-
Rif NPs) were prepared using a 32 randomized full factorial 
design. Accordingly, 9 possible combinations of experimental 
trials were prepared with three replicates. The concentration 
of polymer (X1) and concentration of Rif (X2) were selected as 
independent variables, while parameters mean particle size, 
MPS (Y1), and entrapment efﬁciency, EE (Y2), were selected 
as dependent variables (response parameters). The responses 
were analyzed by statistical modeling of interactive and 
polynomial terms. The response surface curves and contour 
plots were prepared to study the effects of independent 
variables. All the statistical operations were carried out using 
Design-Expert software, version 
8.0.7.1 (Stat-Ease Inc., Minneapolis, USA), Statistica (StatSoft, 
Tulsa, USA) and Microsoft Excel 2010 (I) (Gurgaon, India). 
Independent factors at their varied combi- nations in terms of 
coded and their actual values are represented in Table I. 
 
Optimization and Data Analysis. The optimization of 
parameters was carried out by applying response surface 
methodology (RSM) computations using Design Expert® soft- 
ware (version 8.0.5.2, Stat-Ease Inc., Minneapolis, MN), Statistica 
(Stat soft, Tulsa, USA), and Microsoft Excel 2010. Multiple 
regression analysis (MLRA) was used to generate polynomial 
models (including interaction and quadratic  terms) for the 
response variable and its Eq. (1) can be presented as below. 
 
 
Y ¼ b0 þ b1X1 þ b2X2 þ b3X12 þ b4X22 þ b5X1X2 
þ b6X1   X2 þ b7X1X2 ð1Þ  
where b0 is the intercept corresponding to the arithmetic 
average of quantitative outcomes of 9 runs, b1 to b7 signiﬁes 
coefﬁcients calculated from the experimentally observed 
values of Y, and X1 and  X2  stands  for  the  coded  levels  of  
the independent variables. The terms X1X2 represent 
interaction term, while Xi (2) (I = 1 to 2) denotes quadratic 
terms. The main effects, X1 and X2, symbolizes the mean 
outcome because of changing one factor at a time from its low 
to high value, while the interaction terms (X1X2) indicate 
changes in the response parameters when two factors are 
simultaneously changed.  Non-linearity  in the model was  also 
investigated by the polynomial terms (X 2 and X 2). The 
USA)  and  Microsoft  Excel  2010  (I)  at  a  signiﬁcance  level  of  
p < 0.05. In addition, 3D response surface curves, and the 2D 
contour plots were also developed by the Statistica® software 
(Stat Soft, Tulsa, USA). The best ﬁtting mathematical model was 
chosen by comparing various statistical parameters such as the 
coefﬁcient of variation (CV), the multiple correlation coefﬁcient 
(R2), adjusted multiple correlation coefﬁcient (Adj R2), and the 
predicted residual sum of squares (PRESS). For the chosen 
model, smaller the PRESS value in relation to the other models 
under consideration signiﬁes how well the model ﬁts the data (19). 
 
 
 
 
Characterization of OC-Rif Nanoparticles 
 
Mean Particle Size and Zeta Potential. Dynamic light 
scattering (DLS) and laser Doppler velocimetry (LDV) was 
employed to measure particle size (expressed as mean 
hydrodynamic diameter and polydispersity index; PDI) and 
surface charge (zeta potential) of the particles respectively 
using Zetasizer, Nanoseries Instrument (Nano 25, Malvern 
Instruments, Worcestershire, UK). The nanoparticles were re-
dispersed in deionized water and bath sonicated 
(Ultrawave Ltd., UK) for 5 min and the resultant  samples  
were examined for particle size and zeta potential. 
 
R i f a m p i c i n  L o a d i n g  a nd E n c a p s u l a t i o n  
Efficiency. Encapsulation of rifampicin in NPs was evaluated 
by dissolving OC-Rif NPs in methanol and analyzed using 
UV-VIS spectrophotometer. A known weight of Rif loaded 
nanoparticles was suspended in methanol, allowed to stand 
for around 10–15 min and water was added in a sufﬁcient 
amount to precipitate OC. The suspension obtained was 
centrifuged (Bio Rad Centrifuge, UK) and the concentration 
of rifampicin in the supernatant was determined using UV- 
VIS spectrophotometer (Jenway UV/Vis Spectrophotometer, 
Staffordshire, UK) at 475 nm (22) (Benetton et al., 1998). 
Analysis was performed in triplicate for each batch of drug 
loaded NPs. The yield, drug loading and encapsulation 
efﬁciency were calculated using following formulae and 
presented as mean of each of the parameter: 
 
 
Yield   % 
   Weight    
of NP recovered 
x 100 
Weight of Drug; polymer and excipient 
ð2Þ 
Drug Loading  % 
Weight  of Rif in NP 
x 100 3 
Weight of NP recovered 
Entrapment  Efficiency % 
Weight  of   Rif  in  NP 
100 4 
Weight of Rif fed initially 
1 2 
polynomial equation as mentioned above was utilized to 
interpret the results based on the values of magnitude of 
coefﬁcients and the accompanying positive (synergistic effect) 
or negative sign (antagonistic effect) (21). 
Statistical validity of the polynomials was determined using 
ANOVA as provided in the Design-Expert ®software (Stat-Ease, 
Morphology Determination by Scanning Electron 
Microscopy. Lyophilized nanoparticles were observed using 
scanning electron microscopy (SEM) to study their shape and 
surface morphology. The samples were mounted onto the 
 ¼ 
ð Þ ¼ 
 
Table I. Factorial Design Parameters for Optimization of OC-Rif Nanoparticles 
 
Independent Factors Levels used, actual (coded value) 
 
 
 
 
 
 
 
Formulation of the nanoparticles utilizing 32 factorial design (Coded values) 
 
 
 
 
 
SEM sample holder and gold coated in a  vacuum  chamber 
and images were recorded at the required magniﬁcation at 
the acceleration voltage of 10 kV using FEI XL30 TMP 
Scanning electron microscope (FEI XL30 TMP, Philips, 
Netherlands). 
 
Transmission Electron Microscopy. Nanoparticles were 
also visualized by transmission electron microscopy (TEM). 
Brieﬂy, a drop of nanoparticle suspension was stained with 
phosphotungstic acid and placed on a coated carbon grid and 
vacuum dried. The grid was then examined immediately 
under TEM (Philips Electron  Optics  BV,  Netherlands)  and  
the electron micrographs were obtained. 
 
Differential Scanning Calorimetry and X-ray Powder 
Diffraction Studies. A differential scanning calorimeter 
(DSC Q 2000, TA Instruments, USA) was used to determine 
the thermal properties of the freeze-dried nanoparticles (OC- 
Rif-NPs) and rifampicin. Correctly weighed samples (around 
3–5 mg) of the stated materials were placed in hermetically 
sealed aluminum pans; a sealed empty aluminum pan was 
used as a reference. Heating runs for each sample were set 
from 10°C to 300°C at 10°C min−1 in a nitrogen atmosphere 
to get the heating scan (thermographs). X-ray powder 
diffractometry was carried out using an X-ray diffractometer 
(Oxford Diffraction Xcalibur novaT, UK) and diffractograms 
obtained were analyzed to understand physical state of the 
powder. The samples were mounted on a sample holder and 
X-ray powder diffraction (XRD) patterns were recorded in 
the range of 5–50° at the speed of 5° per min. 
 
 
 
Aerosolization and Aerosol Characterization Using Twin- 
Stage Impinger 
 
The aerosolization of OC-Rif nanoparticle formulations 
was determined following nebulization using a TSI (Glass 
Impinger, Apparatus A Ph. Eur; Copley Scientiﬁc Ltd., 
Nottingham, UK) as per the speciﬁcations given in the 
European Pharmacopoeia (23). In brief, lyophilized OC-Rif 
NP samples (10 mg) were prepared by dispersing in 5 ml 
deionized water. The required volume (5 ml) was loaded into 
a PariBoy air-jet nebulizer with Inhaler Boy compressor (Pari 
Medical, UK). The aerosol generated was directed  into  the  
TSI via a mouthpiece adaptor, and a vacuum pump set at a 
ﬂow rate of 60 L/min was used to draw the aerosol through 
the impinger. The upper and lower stages (stage 1 and stage 
2) of the TSI were ﬁlled with 7 and 30 ml of deionized water 
respectively. The nebulization was performed until aerosol 
generation stopped (nebulizer dryness). Thereafter, the 
nebulizer was gently tapped to achieve maximum output. 
Samples from stages 1 and 2 of TSI were rinsed with small 
known quantities of methanol and made up to 20 and 25 ml 
respectively with deionized water. The amount of rifampicin 
deposited in each stage and that remaining in the nebulizer 
was determined using UV-VIS spectrophotometer (Jenway 
UV/Vis Spectrophotometer, Staffordshire, UK). The aerody- 
namic behavior of the nanoparticle suspension was evaluated 
by calculating nebulization efﬁciency (NE) and ﬁne particle 
fraction (FPF) using Eqs. 5 and 6 (8,24). The effective size cut-
off between stages for the TSI is 6.4 μm; thus, drug deposited 
in stage 2 is the ﬁne particle dose (FPD) and the proportion of 
aerosol generated aerosol deposited in stage 2 is considered 
the FPF, representing that proportion of delivered product in 
nebulized droplets having aerodynamic diameter less than 6.4 
μm, and predicted to be likely to deposit in the lower airways. 
Experiments were performed in triplicate and mean values of 
each parameter are reported. 
 
Nebulization efficiency 
aerosolized drug mass         
x 100 
drug mass loaded in nebulizer 
ð5Þ 
 
Fine particle fraction %
 amount of drug in stage 2 
x 100 
amount of drug in stage 1 and 2 
ð6Þ 
 
In vitro Release Studies 
 
Rifampicin-loaded OC nanoparticles were  tested  for 
their  ability  to  release  rifampicin   from   the   OC-Rif   NPs. 
In vitro release study was carried out in the dark with a 
 
Low (− 1) Medium (0) High (+ 1) 
X1—OC concentration (mg) 50 75 100 
X2—Concentration of Rif (mg) 
Dependent variables 
5 
Constraint 
10 15 
Y1 = Particle Size nm Minimize   
Y2 = % EE Maximize   
Variables/batch no. C1 C2 C3 C4 C5 C6 C7 C8 C9 
X1 − 1 − 1 − 1 0 0 0 +1  +1  +1  
X2 − 1 0 + 1 − 1 0 + 1 − 1 0 + 1 
OC octanoyl chitosan          
 
 ð    Þ ¼ ð Þ 
 
dialysis method using modiﬁed release technique (25). 
Simulated lung ﬂuid (SLF—pH 7.4) with 200 μg/ml of 
ascorbic acid (to prevent oxidative degradation of rifampi- 
cin) was used as the dissolution medium. A known amount 
of OC-Rif NPs (10 mg) was dispersed in SLF and 
transferred to dialysis membrane of which one end was 
previously sealed with dialysis tubing clamp. After com- 
plete transfer of the formulation, another end of the 
dialysis membrane was sealed and placed in a beaker 
containing 25 ml of SLF as external release media under 
stirring at 37 °C. At selected time intervals, suitable 
aliquots were withdrawn from the external medium, diluted 
as required, and analyzed by HPLC (Agilent Technologies 
1200 series) at 335 nm (26). Sink condition was maintained 
(after withdrawal of aliquot at each time points) by 
replenishing the same amount of blank media. The 
experiment was carried out in triplicate and results of the 
release study were plotted as percent cumulative drug 
release vs time. 
 
HPLC Analysis. The amount of rifampicin released 
from OC-Rif NPs was analyzed by HPLC (Agilent 
Technologies 1200 series) equipped with a UV detector to 
quantify the amount of rifampicin release. The injection 
volume was 10 μl. Chromatography was performed with a 
column (Ascentis C18, 150 × 4.6 mm, 5 μm, Supelco, 
Sigma-Aldrich, USA). Mobile phase comprised tetrahydro- 
furan (THF)/phosphate buffer (30/70%) at a ﬂow rate of 
1.0 ml/min and a detection wavelength of 335 nm (26). The 
column temperature was set to 40 °C. The retention time 
of rifampicin was 3.5 min. A calibration curve of pure 
rifampicin was prepared at concentrations ranging from 5 
to 80 μg/ml and was used for quantiﬁcation of rifampicin in 
samples. 
 
 
 
Cytotoxicity of Octanoyl Chitosan Derivative on A549 Cells 
Determined by MTT Assay 
 
The MTT cell proliferation assay for OC was performed 
using the MTT dye reduction assay according to the method 
described by Kroll et al. (27). The cytotoxicity proﬁles of OC 
were studied in the adenocarcinomic human alveolar basal 
epithelial cell line (A549) over the period of 48 h. The cells 
(passage no. 45–49) were cultured in 96-well plates with 100 μl 
complete medium [RPMI-1640, supplemented with fetal bovine 
serum (10%, FBS) and antimycotic antibiotic solution (1%)] 
and incubated at 37 °C (5% CO2 incubator) for the period of  
24 h. Samples (100 μl) were prepared in complete medium and 
added to the wells in a concentrations ranging from 0 to 5 mg/ml 
and incubated for a further 48 h. After incubation, 40 μg/ml 
MTT solution (5 mg/ml in PBS, pH 7.4) was added to each well 
and the plates were again incubated for 2 h at 37 °C (5% CO2 
incubator). Medium was carefully replaced with 100 μl of 
DMSO in each well to solubilize formazan crystals and the 
absorbance was read at 570 nm using an ELISA plate reader 
(SpectraMAX 190, Molecular Devices). The results from the 
MTT experiments were graphed as percentage of cell growth in 
comparison to the control wells containing only the cells in the 
medium and dimethyl sulfoxide (DMSO, 10%) as a positive 
control. The relative cell viability (%) was calculated using the 
following equation: 
Cell  viability  % 
  OD   of test  well 
x 100 7 
OD of reference well 
 
 
Stability Study 
 
Lyophilized OC-Rif NPs were stored in desiccator for 
2 months at ambient room temperature (20–25 °C) to 
determine their stability. After  2  months  storage,  samples  
(2 mg) were taken to determine particle size and percentage 
of rifampicin in the formulation (OC-Rif NPs). 
 
Statistical Analysis 
 
Experiments were performed in triplicate and the data 
collected are expressed as the mean value ± standard 
deviation. Results of the factorial design were statistically 
analyzed using ANOVA (Microsoft Excel Corp, India) and 
Statistica (Stat soft Inc., Tulsa, USA) by generating various 
polynomial equations. 
 
RESULTS AND DISCUSSION 
 
Preparation of Nanoparticles and Characterization 
 
Chitosan nanoparticles have previously been prepared 
using many methods such as ionic gelation, complex coacer- 
vation, emulsion cross-linking, and spray drying (28). In 
addition, polymeric micelles (amphiphilic, self-assembly) 
prepared using modiﬁed chitosan derivatives have also been 
explored for drug delivery (12,29–31). However, there are no 
reports of the preparation of nanoparticles directly from 
hydrophobic chitosan derivatives (OC) using the double 
emulsion solvent evaporation (DESE) technique without 
cross-linking. Hence, the current investigation assessed the 
feasibility of using OC in the preparation of nanoparticles 
(NPs) and examined the incorporation of rifampicin into OC 
NPs as a system for the potential treatment of TB via 
pulmonary route. The DESE method was successfully utilized 
for the preparation of NPs from OC. Initially, blank OC NPs 
were prepared and preliminary experiments helped to select 
optimal parameters such as sonication time, solvent, surfac- 
tant, and concentration of surfactant (results are given in 
supporting information). Once the preliminary parameters 
were chosen, rifampicin-loaded OC NPs were prepared and 
optimized employing a 32 factorial design. 
Optimization of Formulation by Factorial Design 
 
Based on the preliminary formulation optimization 
studies, various process parameters required for preparation 
of OC NPs were selected, which helped to avoid the 
complexity of experimental design. Thus, optimized parame- 
ters such as organic phase (DCM—3.5 ml); internal aqueous 
phase (0.5 ml); external aqueous phase (10 ml, 0.5% PVA); 
sonication pulse (15 W); and sonication times of 15 and 30 s 
for primary and secondary emulsion respectively were kept 
constant in factorial design studies. Inﬂuence of parameters 

 ð Þ ¼ ð Þ 
 
such as concentrations of OC (X1) and rifampicin (X2) were 
optimized by applying a 32 factorial design of experiment 
consisting of nine formulation batches with random variation 
of rifampicin and OC at three levels. Table II shows the 
combination of independent variables and observed re- 
sponses in terms of mean particle size, entrapment efﬁciency, 
and other parameters (PDi, zeta potential, yield and drug 
loading, etc.) for all the nine formulations. 
 
Effect of Formulation Variables on the Response Parameters 
 
Nine formulations of OC-Rif nanoparticles were pre- 
pared according to the 32 factorial design and correlation 
between independent factors and their response parameters 
in terms of MPS and EE was statistically analyzed using 
ANOVA (Microsoft Excel Corp, India) and Statistica  Stat  
soft Inc. (Tulsa, USA) by generating various polynomial 
equations, response surface and contour plots. The data 
analyzed from the software show the effects of variables on 
the respective response parameters (Y1 and Y2). 
Results of response variables obtained from design of 
experiment (DoE) were ﬁtted in a simple linear equation, 
interactive equation or quadratic model equation (Eqs. 8, 9, 
and 10 respectively) using multiple regression analysis and F- 
statistic to determine statistically signiﬁcant terms. 
 
Y ¼ b0 þ b1X1 þ b2X2 ð8Þ  
Y  ¼ b0  þ b1X1  þ b2X2 þ b12X1X2 ð9Þ  
Y ¼ b0  þ b1X1  þ b2X2  þ b11X11  þ b22X22 þ b12X1X2 ð10Þ 
 
Multiple regressions analysis revealed no signiﬁcant inﬂu- 
ence of factors X1, X2, and X22 on the response parameter MPS, 
while factors X2 and X22 were found to be statistically signiﬁcant 
(p < 0.05) for % EE. The multiple regression analysis suggested 
quadratic models as shown in Eqs. 11 and 12 for both MPS and 
EE respectively. The observed and predicted values of MPS and 
EE for all the batches of OC-Rif NPs are tabulated in Table III 
along with their percent relative error (%RE) values as 
calculated using Eq. 13. 
 
 
Y1 ¼ 217:71 þ 24:89 X1 þ 16:91 X2 þ 19:32 X11 
þ 37:11 X22 þ 11:44 X1X2 ð11Þ 
 
Y2 ¼ 23:81−1:32 X1 þ 12:76 X2 þ 4:97 X11 þ 20:08 X22−2:48 X1X2 
ð12Þ 
 
%Relative error   RE 
 observed Ps−predicted Ps 
x 100 13
 
predicted Ps 
 
Regression output and full model responses for depen- 
dent variables, namely MPS and EE of formulation OC-Rif 
NPs are displayed in Table IV. The MPS  and  EE  observed  
after random combinations of three levels of two independent 
variables (X1 and X2) were subjected to multiple regression 
analysis which revealed statistical signiﬁcance (p < 0.05) of the 
full model second-order polynomial equation for  MPS  and  
EE. In a multiple regression analysis, values of Bprobability > 
F^ less than 0.05 indicate that model terms are signiﬁcant. In 
this experiment, analysis of the full model polynomial 
equation showed Bprobability < F^ (0.012), and hence model 
terms are signiﬁcant (Eqs. 10 and 11). 
The F values for MPS and EE obtained by full model were 
found to be 25.33 and 45.33 respectively, while corresponding 
calculated F values (Fcal) were 0.34 and 0.11 (p > 0.05) 
respectively, indicating signiﬁcance (p > 0.05). In addition, the 
goodness of ﬁt of the model was established using the 
correlation coefﬁcient (R (2)). The correlation coefﬁcient (R2) 
values of MPS (0.98) and EE (0.99) showed the total variability 
in the model. The value of adjusted correlation coefﬁcient (adj 
R2) for MPS was found to be 0.9383, whereas 0.9652 for EE as 
obtained from the full model regression analysis. The predicted 
R2 values of MPS and EE were found to be in reasonable 
agreement with the adj R2 values, suggesting statistical 
signiﬁcance of the model (R2 value very close to 1), 
demonstrating very good correlation between the independent 
variables. Thus, closeness of R2 values to 1 for both MPS and EE 
indicated   accuracy   of   the   model.   Moreover,   values of 
Bprobability > F^ were greatly less than 0.05, implying that the 
model’s terms viz. concentration of OC and Rif are statistically 
signiﬁcant   (p   value   < 0.05).   Together,   all   of   the above 
considerations indicate that the model can effectively explain 
99% variation around the mean value. 
It was observed that, the MPS values ranged from 208.17 
± 26.81 nm to 323.57 ± 65.80 nm and entrapment efﬁciency 
(EE) of Rif in OC NPs was between 25.4 ± 3.77% and 64.86 ± 
7.73%. A considerably higher entrapment of rifampicin 
(64.86 ± 7.73%) was achieved at low levels (−  1)  of  X1  
(50 mg) and high level of X2 (15 mg) from batch C3. 
Equations 10 and 11 display the quantitative effect of 
formulation components (independent variables X1 and X2) 
on response parameters (Y1 and Y2), in the form of 
corresponding polynomial equations and regression coefﬁ- 
cients for mean particle size (MPS—Y1) and mean % 
entrapment efﬁciency (EE—Y2). 
Each coefﬁcient in equations 10 and 11 was evaluated 
and the signiﬁcance determined on the basis of the p values,  
as shown in Table IV. The smaller the p value (p < 0.05), the 
more statistically signiﬁcant is the corresponding coefﬁcient. 
The data obtained from the full model of MPS conﬁrms that 
the main effects of the independent variables (X1,  X2,  and  
X22) were statistically signiﬁcant for prediction of MPS as  
their p values were well below 0.05 (p < 0.05), while the 
interaction  term  X1X2  had  little  predictive  effect  as  their   
p values were above 0.05 (p > 0.05) and hence were excluded 
from the model. From the results of EE, p values below 0.05  
(p < 0.05) were noted for the independent variables X2, X22 
suggesting their statistical signiﬁcance. Remaining factors 
such as X1, X11 and  the  interaction  term  X1X2  had  p  values 
(p > 0.05), and therefore they were considered less important 
in the given model. 
The coefﬁcients of the two independent variables in 
quadratic Eq. 10 were compared and the coefﬁcient value for 
 
 
 
Table II. Response Parameters for NPs Prepared Using 32 Factorial Design 
 
Batch OC (mg) Rif (mg) MPS (Y1) (nm) PDI ZP (mV) Yield (%) DL (%) EE (Y2) (%) 
C1 50 5 242.8 ± 44.36 0.300 ± 0.08 18.83 ± 8.44 60.79 ± 1.43 2.88 ± 0.66 36.83 ± 9.35 
C2 50 10 214.4 ± 26.58 0.292 ± 0.04 20.57 ± 8.17 59.88 ± 1.93 4.37 ± 0.18 28.77 ± 0.44 
C3 50 15 253.43 ± 19.06 0.323 ± 0.06 23.33 ± 2.83 62.49 ± 3.63 13.51 ± 0.81 64.86 ± 7.73 
C4 75 5 242.37 ± 55.54 0.536 ± 0.27 28.8 ± 3.13 65.31 ± 4.73 1.64 ± 0.16 27.87 ± 4.46 
C5 75 10 208.17 ± 26.81 0.426 ± 0.14 29.03 ± 13.27 64.84 ± 4.55 2.89 ± 0.26 25.4 ± 3.77 
C6 75 15 276.8 ± 58.58 0.327 ± 0.11 25 ± 3.035 65.24 ± 4.24 9.58 ± 1.03 58.33 ± 7.27 
C7 100 5 267.2 ± 24.98 0.482 ± 0.03 35.9 ± 2.066 69.29 ± 2.40 1.79 ± 0.13 38.62 ± 4.06 
C8 100 10 269.2 ± 107.55 0.447 ± 0.04 31.67 ± 1.79 68.10 ± 1.71 2.49 ± 0.03 27.21 ± 0.94 
C9 100 15 323.57 ± 65.80 0.413 ± 0.19 27.3 ± 6.49 68.55 ± 2.46 7.52 ± 0.02 56.72 ± 2.04 
n = 3; mean ± Standard Deviation 
OC—octanoyl chitosan; Rif—rifampicin; MPS—mean particle size; PDI—polydispersity index; EE—entrapment efﬁciency; DL—drug loading; 
ZP—zeta potential. 
 
X1 (b1 = 24.89) was found to be maximum suggesting it was 
the major contributing factor which affects the mean particle 
size of OC-Rif NPs. On the other hand, quadratic Eq. 11 
showed maximum coefﬁcient values for independent variable 
X2 (b1 = 12.76), and hence it was the major factor affecting  
EE. In both cases, positive values of X1 and X2 are an  
indication of synergistic effect of OC and rifampicin concen- 
tration on MPS and EE. Signiﬁcance  of  quadratic  model  
terms X1 and X2 in Eq. 10 (MPS), and  signiﬁcance  of  
quadratic terms X2 and X22 in Eq. 11 (EE) suggested non- 
linearity (non-signiﬁcant) in the ability of independent 
variables (X1 and X2) to inﬂuence MPS and EE respectively. 
The combined effect of factors X1 and X2 can be further 
elucidated with the help of contour plots and response surface 
curves as shown in Figs. 1a, b and 2a, b. 
The predicted residual sum of squares (PRESS) is also 
known as sum of squared residuals (SSR) or the sum of 
squared errors of prediction (SSE). PRESS values indicate  
how well the model ﬁts the data, and it is recommended that, 
for the chosen model the value of PRESS should be relatively 
small as compared to the other models under consideration 
(32). The polynomial model which shows lower PRESS value 
determines the ﬁtness of data, and hence such model is 
selected. In the given experiment, PRESS value was calcu- 
lated for the full and reduced polynomial model for both the 
independent variables (Y1 and Y2). Results indicated the 
suitability of the full polynomial model as compared to the 
reduced model, with smaller PRESS values for both Y1 
(223.96) and Y2 (24.73), whereas the reduced model showed 
higher PRESS values for Y1 (1493.53) and Y2 (109.17). 
Figures 1a, b and 2a, b show contour plots and 3D 
response surface plots for both response parameters;  MPS 
and EE respectively, depicting the effects of independent 
variables X1 and X2 on dependent variables Y1 and Y2. No 
signiﬁcant difference in the MPS and EE was noted, when the 
value of X1 was varied from low (− 1) to high (+ 1) level, 
keeping X2 constant at low level (− 1). In the similar set up of 
experiment, when the value of X2 was increased from low 
level (− 1) to medium level (0), a non-signiﬁcant decrease in 
the particle size was noted which also led to corresponding 
nonsigniﬁcant decrease in the % EE. Further increase in the 
concentration of X2 signiﬁcantly increased EE, while a 
nonsigniﬁcant increase of MPS was observed. Comparing  
MPS, it was observed that small MPS values in the range of 
208.17 ± 26.81 to 323.57 ± 65.80 nm were obtained from all the 
batches (C1 to C9), with smallest MPS obtained at medium 
level of X1 and X2 from batch C5. The same batch 
demonstrated the smallest EE (25.4 ± 3.77%). In a different 
combination, where values of X2  were  increased  from  low  
(−  1)  to  high  (+ 1)  level  and  X1  kept  constant  at  low level 
 
 
Table III. Observed and Predicted Values of Response Parameter—MPS (Y1); EE (Y2) 
 
Batch Predicted Y1 Observed Y1 Residual Y1 %RE Y1 Predicted Y2 Observed Y2 Residual Y2 %RE Y2 
 
C1 243.78 242.80 ± 44.36 − 0.975 − 0.399 34.93 36.83 ± 9.35 1.89 5.43 
C2 212.14 214.40 ± 26.58 2.26 1.065 30.09 28.77 ± 0.44 − 1.33 − 4.41 
C3 254.72 253.43 ± 19.06 − 1.285 − 0.504 65.43 64.86 ± 7.73 − 0.57 − 0.87 
C4 237.91 242.37 ± 55.54 4.46 1.875 31.13 27.87 ± 4.46 − 3.26 − 10.46 
C5 217.71 208.17 ± 26.81 − 9.54 − 4.382 23.81 25.40 ± 3.77 1.58 6.65 
C6 271.72 276.80 ± 58.58 5.08 1.869 56.66 58.33 ± 7.27 1.67 2.95 
C7 270.69 267.20 ± 24.98 − 3.485 − 1.288 37.26 38.62 ± 4.062 1.36 3.65 
C8 261.92 269.20 ± 107.55 7.28 2.779 27.46 27.21 ± 0.94 − 0.26 − 0.93 
C9 327.37 323.57 ± 65.80 − 3.795 − 1.159 57.83 56.72 ± 2.037 − 1.10 − 1.91 
n = 3, mean ± SD 
MPS—mean particle size; EE—entrapment efﬁciency 
  
Table IV. Response of Full Model of OC-Rif NPs 
 
MPS EE 
 
 
Coefﬁcients p value  Coefﬁcients p value 
X1 24.890 0.0059* − 1.317 0.343 
X2 16.905 0.0173* 12.76 0.002* 
X11 19.320 0.0508 4.969 0.092 
X22 37.105 0.0089* 20.08 0.002* 
X1X2 11.435 0.0772 − 2.482 0.1823 
Intercept 217.71 5.69E-05# 23.81 0.0016# 
*Statistically signiﬁcant (p < 0.05) 
# Signiﬁcance of F value 
MPS—mean particle size; EE—entrapment efﬁciency 
 
(− 1), results showed non-signiﬁcant decrease in value of MPS 
(214.4 ± 26.58 nm) initially at the medium level of X1 (0), 
which further increased (253.43 ± 19.06 nm) at high level (+ 1) 
of X1. Entrapment efﬁciency also showed similar trend (28.77 
± 0.44%  (X1  −  0)  and  64.86 ± 7.73%  (X1 − + 1))  with  in- 
creased concentration of Rif. Among all the batches tested, 
optimum MPS with maximum EE was obtained with batch 
C3, formulated with the combination of low  level  of  X1  
(50 mg) and high (+ 1) level of X2 (15 mg). The results can be 
observed from the contour plots and 3D response surface plot 
as displayed in Figs. 1a, b and 2a, b. The predicted and 
observed values of response parameter (MPS and EE) are 
shown in Table III. Low percent relative error values (below 
10%) and small residuals were demonstrated by the full 
polynomial model of MPS and EE (Table IV), conﬁrming the 
reasonable agreement between predicted and experimental 
values and indicated suitability of the model. ANOVA full 
model results of MPS and EE are given in Table V. 
 
Effect of Polymer Concentration and Theoretical Drug 
Loading on MPS, EE, and ZP 
 
A non-signiﬁcant inﬂuence of theoretical drug loading 
(DL) on MPS was observed at all levels. Theoretical DL of 5, 
10, and 15 mg of rifampicin resulted in MPS of 242.8 ± 44.36, 
214.4 ± 26.58, and 253.43 ± 19.06 nm respectively. Similar 
results were obtained even when the concentration of 
polymer was increased from 50 to 75 and 100 mg. Such a 
relation between the theoretical DL and polymer concentra- 
tion on MPS was also observed by Doan et al. (33). Although 
MPS  from  all  the  batches  were  obtained  in  the  range  of 
208.17 ± 26.81 to 323.57 ± 65.80 nm, larger MPS was observed 
when the concentration of polymer and drug was increased. 
Formulation C1–C3 consisting of lowest concentration of OC 
(50 mg) and varying amounts of Rif (5–15 mg) showed lowest 
values of PDI (0.292 ± 0.036 to 0.323 ± 0.059), whereas 
increasing concentration of OC to 75 and 100 mg led to 
increase in the PDI values suggesting broader particle 
distributions (PDI > 0.4). Non-signiﬁcant increases  in  the 
MPS (276.8 ± 58.58 nm and 323.57 ± 65.80 with PDI of  0.427 
± 0.107 and 0.413 ± 0.188) with increased amount of OC (75 
and 100 mg) may be due to an increase in the viscosity of the 
organic phase in the emulsion, which might have caused 
hindrance in the efﬁciency of sonication. Reports have also 
suggested possible collision and merger of nanoparticles 
leading to large MPS, when higher polymer  concentration  
was used for the preparation of NPs (34,35). Based on the 
results of this study, batch C3 composed of 50 mg of polymer 
and 15 mg of Rif exhibited optimum particle size with  
uniform size distribution as compared to other batches 
prepared with other combinations of OC-Rif concentration. 
Factorial design of experiment yielded formulation batches 
with the variable entrapment efﬁciencies of Rif in OC. At low 
polymer concentration (50 mg), the highest entrapment efﬁ- 
ciency (64.86 ± 7.73%) was obtained, when the theoretical DL 
was kept at a higher level of 15 mg (batch C3). Similar pattern of 
results in terms of increased EE was observed when the amount 
of OC was increased to 75 and 100 mg in batch C6 and C9 with 
the corresponding EE of 58.33 ± 7.27 and 56.72 ± 2.037% 
respectively. The  use  of  the  highest  OC  concentration 
(100 mg) for the preparation of NPs led to non-signiﬁcant 
decrease in the EE, which may be due to enhanced viscosity of 
the system contributing to hampered sonication and stirring 
(36). Considerably lower EEs of 36.83 ± 9.35% and 28.77 ± 
0.44% were noted at lower theoretical DL of 5 and 10 mg 
 
 
Fig. 1. a Contour plot showing the effect of independent factors on mean particle size (MPS). b Response surface plot showing the effect of 
independent factors on MPS 
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Fig. 2. a Contour plot showing the effect of independent factors on entrapment efﬁciency (EE). b Contour plot showing the effect of 
independent factors on EE 
 
respectively. The same trend was noted in all the batches 
studied. Thus, a non-signiﬁcant change in the entrapment 
efﬁciency was observed at low and medium theoretical drug 
loading at all polymer concentrations, while high theoretical 
drug loading showed increased entrapment efﬁciency, which 
may be due to higher amount of drug available for entrapment. ( 
37,38) Similar results have been reported previously (39,40). 
Other studies have also reported increased  theoretical DL 
associated with increased EE and size (41,42). PDI relates to the 
distribution of particle sizes in a sample of particles. Smaller PDI 
values close to 0 are preferred, indicating a narrow size 
distribution (43). Results of this study demonstrated acceptable 
PDI values at low polymer concentration, while higher PDI 
values (> 0.4) were observed for the batches prepared using 
higher amounts of OC (Table II). 
A positive zeta potential conferred by the polymers is usually 
preferred in the delivery of small molecules and macromolecules 
due to advantages such as ease in surface assimilation of 
negatively charged materials such pDNA and RNA, drugs, and 
even proteins, and their ability to interact with cells thereby 
providing high transfection efﬁciency (44). Moreover, cationic 
polymers have also been explored for the puriﬁcation of water 
(45). The current investigation was directed to modify chitosan 
 
 
Table V. Analysis of Variance (ANOVA) of MPS and EE for Full 
Models of OC-Rif NPs 
while retaining its positive charge. All the batches from C1 to C9 
showed positive ZP ranging from + 18.83 ± 8.44 to + 35.90 ± 
2.07 mV. Although no correlation between charge on the particles 
and amount of drug was seen, increasing the polymer concentra- 
tion had a positive inﬂuence on the charge. This enhancement in 
the ZP can be rated as C1< C4 < C7 (+ 18.83 ± 8.44 <+ 28.8± 
3.13 <+ 35.90 ± 2.07 mV) and C2< C5 < C8 and C3 < C6< C9, 
with respect to increase in polymer concentration. Increased ZP 
values for rifampicin-loaded OC NPs, as compared to their blank 
counterparts were observed. This increased ZP could be 
attributed to the particle-associated rifampicin (adsorbed), which 
might have inﬂuenced surface charge owing to the presence of 
amino groups in the rifampicin molecule (46). 
 
Optimization of Responses Using Desirability Function (47) 
 
The difﬁculty of multiple and sometimes opposing 
responses is usually overcome by an optimization technique 
involving desirability function. Each response is afﬁliated with 
its own partial desirability function. The value of 1 for the 
desirability function is always preferred as it is considered 
optimal, while value of zero means the result is treated 
unacceptable. The desirability for each response can be 
calculated at a given response point in the experimental 
design. When the goal is to minimize the given response, the 
following formula can be used to calculate individual 
desirability. 
 
Results of MPS di   Yi 
 Yi ðmpsÞ−Ui 
Ti−Ui ð14Þ 
 
where d1 is individual desirability, Yi (mps) is experimental 
results of response MPS. Ui and Ti stand for maximum and target 
MPS respectively. Similarly, if one wants to maximize the stated 
response, Eq. 15 can be used to calculate individual desirability. 
 
 
df—degrees of freedom; SS—sum of squares; MS—mean of squares; 
F Fischer’s ratio; R2 regression coefﬁcient; MPS—mean particle size; 
EE—entrapment efﬁciency 
di   Yi 
 Yi ðeeÞ−Li 
Ti−Li ð15Þ 
 df SS MS F R2 Adj R2 
Regression 5 9454.87 1890.97 25.33 0.98 0.94 
Residual 3 223.96 74.65 – – – 
Total 8 9678.83 – – – – 
Results of EE 
Regression 5 1868.55 373.71 45.33 0.99 0.97 
Residual 3 24.73 8.24 – – – 
Total 8 1893.28 – – – – 
 
  
where d1 is individual desirability, Yi (e) is experimental 
results of response MPS. Ti and Li stand for minimum and 
target EE respectively. Once we get this, we can calculate 
combined desirability (D) using Eq.16, which involves 
multiplication of individual desirability. 
 
 
D ¼ 
  
d1ðY1Þ x d2 ðY2Þx………::x dnðYnÞ
 
1=k ð16Þ 
where, k denotes total number of responses. 
Optimum parameters for the formulation were gener- 
ated utilizing a numerical optimization technique by the 
desirability function approach. Response parameters such as 
Y1 and Y2 were optimized and the optimized formula was 
ﬁnalized by keeping the mean particle diameter in the range 
200 to 300 nm and EE between 50 and 70%. Batch C3 
(containing low (− 1) level of variable X1 and high level of 
variable X2) resulted in the optimum formula. Individual 
desirability for MPS and EE  was calculated and found to  be   
1, indicating acceptability of the model for the optimization of 
formula. Similarly, overall desirability for the current model 
was also found to be 1, indicating suitability of the model for 
optimization purposes. Moreover, the result of the experi- 
mental and predicted values for MPS and EE conﬁrmed the 
practicability and validity of the model. Relative errors for 
both MPS and EE were found to be below  10%  indicating 
that the response surface methodology (RSM) optimization 
technique was appropriate for optimization for the prepara- 
tion of NPs from the novel polymer and for incorporation of 
Rif in OC NPs. 
 
Optimized Formulation 
 
The rigorous optimization process yielded a ﬁnal formula 
(Table VI), which was used in further studies. Table VI also 
shows the predicted and observed values of various 
parameters. 
Lyophilization of OC-Rif NPs  was  done in  the presence 
of trehalose as a cryoprotective agent at a concentration of 
1% (20). Almost comparable results with respect to mean 
particle size were achieved in the samples before (231.9 ± 
20.37) and after lyophilization (253.43 ± 19.06 nm), with no 
signiﬁcant change in mean size following lyophilization (P> 
0.05). This has indicated the suitability of trehalose (1%) as a 
cryoprotectant during lyophilization. 
Particle Characterization 
 
Particle Size and Surface Charge 
 
OC-Rif NPs prepared using the optimized ﬁnal formula 
were centrifuged and washed to remove any unentrapped 
materials (Rif and PVA) and mean hydrodynamic diameter, 
PDI, and zeta potential were determined prior to freeze  
drying (FD). The preparation had mean particle size of 231.9 
± 20.37 nm, PDI of 0.384 ± 0.022, and ZP of + 28.2 ± 1.67 mV. 
After redispersion of freeze-dried OC-Rif-NP powder, the 
measured values for MPS, PDI, and ZP were very similar 
(Table VI). 
 
Morphology of OC-Rif NPs After Freeze Drying 
 
The size, shape, and surface morphology of nanoparticles 
were visualized by scanning and transmission electron mi- 
croscopy (SEM and TEM) (Fig. 3a, b)  respectively.  OC-Rif  
NPs were uniform in size and morphology, showed small 
particle diameter, spherical shape, and smooth surface 
morphology. 
 
Solid-State Characterization of OC-Rif NPs 
 
Differential Scanning Calorimeter 
 
Thermal analysis of rifampicin, OC, OC-Rif physical 
mixture and OC-Rif NPs formulation was performed using  
DSC and the data obtained in the form of thermograms are 
presented in Fig. 4. Thermograms revealed a characteristic 
exothermic peak at 260°C for rifampicin with no endothermic 
and exothermic peak between 20 to 300°C in the thermogram 
of OC. However, an exothermic peak was observed above 
300°C in the thermogram of chitosan, which is attributed to 
monomer dehydration, glycoside bond cleavage and decom- 
position of the acetyl and deacetylated units of chitosan. 
Similar results have been reported previously (48,49). Simi- 
larly, physical mixture of OC and rifampicin did not show any 
endothermic or exothermic peak for OC, but an exothermic 
peak corresponding to rifampicin was observed at 260 °C. 
Owing to the absence of endothermic or exothermic peak in 
OC thermograms, DSC thermographs of OC-Rif NPs formu- 
lation were also devoid of endothermic or exothermic peaks. 
In addition, the absence of a peak for rifampicin in the OC-    
Rif NPs suggested molecular dispersion of rifampicin in OC 
NPs. 
 
Table VI. Optimized Formulation Parameters; Observed and Predicted Values for OC-Rif NPs 
 
Formulation parameters Optimum value Parameters Y1 (nm) Y2 (%) 
OC (mg) 50 Predicted 254.72 65.43 
Vol. of organic phase (ml) 3.5 Observed 253.43 ± 19.06 64.86 ± 7.73 
Rifampicin content (mg) 15 % RE 0.504 0.87 
Vol. of internal aqueous Phase (ml) 0.5 Residuals − 1.285 − 0.57 
Surfactant in external aqueous phase PVA ZP observed + 23.33 ± 2.83  
Concentration of surfactant in external aqueous phase (% w/v) 0.5    
Vol. of external aqueous phase (ml) 10    
OC—octanoyl chitosan; PVA—polyvinyl alcohol     
 
 
 
 
Fig. 3. a Scanning electron micrograph of OC-Rif NPs. b Transmission electron micrograph of OC-Rif NPs 
 
X-ray Powder Diffraction 
 
X-ray diffractograms of rifampicin, chitosan, OC, and OC-
Rif NPs are shown in Fig. 5. Characteristic crystalline peaks at 
2θ values of 13° and 15° for rifampicin were observed in the 
powder XRD diffractograms. XRD of Rif indicated the 
crystalline nature of rifampicin. Parent chitosan (chitosan > 5 
K) showed a characteristic broad peak of moderately low 
intensity at around 20°, whereas a sharp 
 
 
 
Fig. 4. DSC thermograms of a Rif, b Chitosan, c OC, d OC-Rif 
physical mixture, and e OC-Rif NPs 
peak at 20° and a new peak of higher intensity below 2 theta 
value of 8 were observed in the XRD spectra of OC. XRD 
studies revealed a broad diffuse peak for rifampicin-loaded 
NPs (OC-Rif NPs). The absence of crystalline peak of 
rifampicin in the OC-Rif NPs suggested the presence of 
rifampicin in amorphous form in OC NPs and its molecular 
dispersion in OC NPs. Presence of a broad  diffuse  peak  in 
XRD diffractograms of rifampicin-loaded  OC  NPs  is  a  
general characteristic for such systems composed of binary 
components (50). Results from XRD have demonstrated that 
crystallinity of rifampicin was altered by its encapsulation into 
OC nanoparticle formulation. 
 
Aerosol Characterization Using the Twin-Stage Impinger 
 
Samples for TSI studies  were  prepared  by  dispersing  
10 mg of OC-Rif NPs in 5 ml deionized water and nebulized 
using a PariBoy air-jet nebulizer into the TSI (Table VII). 
Following nebulization to dryness 0.45 ± 0.06 mg of RIF 
was deposited in stage 2 of the TSI (i.e. the FPD) representing 
an FPF of 43.27 ± 4.24%. The amount of drug remaining in the 
nebulizer, caused by the residual volume 
(51) of the nebulizer was found to be 0.59 ± 0.06 mg giving a 
nebulizer efﬁciency of 77.04 ± 4.33%. 
These ﬁndings indicate the suitability of the jet nebulizer 
to deliver rifampicin, in a mucoadhesive NP carrier system to 
the lower respiratory tract. Such nebulizers have previously 
been reported to achieve efﬁcient aerosolization of 
nanocarriers (6,52), with the small particles being efﬁciently 
delivered in the relatively large nebulized aerosol droplets 
which are efﬁciently delivered to the lower stage of the TSI 
and human lower respiratory tract. 
 
In vitro Drug Release 
 
The cumulative percentage release of Rif from Rifampi- 
cin  suspension  (Rif-S)  and   OC-Rif   NPs   was   investigated 
in vitro over a period of 2 h and 72 h respectively. Experiment 
was performed in triplicate and release curves plotted as 
cumulative percentage drug release vs time  are  shown  in 
Fig. 6. Simulated lung ﬂuid (SLF 4, pH 7.4) was used as a 
release medium, to mimic the biological environment within 
  
 
Fig. 5. X-Ray diffractograms of a Rif, b Chitosan, c OC, and d OC- 
Rif NPs 
 
 
the lungs into which aerosolized NPs will be deposited. 
Results showed immediate release of almost all the rifampicin 
(87.65 ± 10.29%) from Rif-S into release medium, whereas 
release of rifampicin was retarded from the OC NPs. OC-Rif 
NPs displayed initial rifampicin release of 5.23 ± 3.15%, 
indicating the ability of the polymer matrix to control the 
release of drug. OC-Rif NPs exhibited sustained and steady 
release over the period of study (72 h), with a biphasic drug 
release pattern. Initially, a sustained-release phase was 
observed until 6 h, which was followed by a steady, slower 
 
drug release. In the initial phase (up to 6 h), 45.97 ± 2.99% of 
rifampicin release was noted, which may have been due to 
dissolution and passive diffusion of Rif located on or near the 
surface of nanoparticles. In addition, penetration of aqueous 
release medium (SLF pH 7.4) into the hydrophobic polymeric 
matrix leading to slow dissolution and thereby diffusion of the 
drug from the OC NP matrix may also have caused sustained 
initial release up to 6 h. After 6 h, a slower release of drug 
occurred, leading to loss of 73.14 ± 3.17% of drug at 72 h. The 
second phase of drug release is probably due to the 
diminution of rifampicin in the polymeric matrix, leading to    
a reduced concentration gradient, causing less drug to be 
released. Hence, the biphasic release pattern of the formula- 
tion can be ascribed to the localization of rifampicin onto and 
within the immediate layer and core of the prepared 
nanoparticles. These results agree with the observations 
described by Klariæ et al. (53). 
The release proﬁles obtained were ﬁtted using various 
mathematical models, namely: zero-order, ﬁrst-order, 
Higuchi, Hixon-Crowell, and Korsemeyers-Peppas models to 
explore the kinetics of drug release from OC nanoparticles 
(54). The results of different model ﬁttings are given in Fig. 6. 
Among various models tested, the curve ﬁtting of release data 
to the Korsemeyers-Peppas model gave a higher value of 
correlation coefﬁcient (r2 value of 0.8243) with the Bn^ value 
(0.911,   which  is   0.5 < n < 1),   suggesting  an  anomalous 
transport (non-ﬁckian) mechanism for rifampicin release. 
Thus, the Korsemeyers-Peppas model satisfactorily repre- 
sented the data owing to diffusion of rifampicin from the OC 
NPs. 
 
Cytotoxicity Studies of OC 
 
A very important criterion determining the suitability of 
polymers in drug delivery is their cytotoxicity. Non-cytotoxic 
materials are always preferred while choosing carrier materials 
for drug delivery. Cationic agents are reported usually to confer 
cytotoxicity owing to their interaction with negatively charged 
cellular elements or proteins (55). However, chitosan and its 
derivatives are described as less cytotoxic than other cationic 
polymers (for instance poly-lysine and polyethyleneimine) (56). 
The cytotoxicity caused by chitosan and its derivative is mainly 
determined by the factors such as type of chitosan derivative and 
type of cells under study (54). This study used chitosan 
derivatives and tested the viability of cells treated with OC by 
application of the MTT assay (Fig. 7). Results indicated non- 
signiﬁcant changes in the cell viability at the examined 
concentrations of OC in comparison to the controls (positive 
and negative), demonstrating in vitro biocompatibility of OC 
over the concentration range studied. 
 
Table VII. Aerosol Properties of Nebulized of OC-Rif NPs Measured Using TSI 
 
Batch Dose ﬁlled in 
nebulizer (mg) 
FPD (mg) Dose  remained 
in nebulizer (mg) 
NE % FPF (%) 
Batch C3 (OC-Rif NPs) 1.35 0.45 ± 0.06 0.59 ± 0.06 77.04 ± 4.33 43.27 ± 4.24 
n = 3, mean ± SD 
NE—nebulization efﬁciency; FPF—ﬁne particle fraction; FPD—ﬁne particle dose 
 
 
 
 
Fig. 6. Percent cumulative release of Rif from OC-Rif nanoparticles (n= 3, mean ± SD) 
 
 
 
 
 
Stability Studies 
 
OC-Rif NPs were assessed for their ability to maintain 
their mean particle size and size distribution along with their 
content of rifampicin over the period of 2 months storage at 
ambient temperature (Table VIII). No  signiﬁcant  differ-  
ences (P > 0.05) were observed for drug content, mean 
particle size or PDI values of OC-Rif NPs, conﬁrming the 
stability of OC-Rif NPs at  ambient  room  temperature  (20– 
25 °C). Hence, no special storage conditions were necessary 
up to 2 months. 
 
CONCLUSIONS 
 
This study has shown that derivatization of chitosan with 
a hydrophobic octanoyl chain increased the hydrophobicity of 
the polymer with no cytotoxicity. Octanoyl chitosan was 
successfully utilized to prepare nanoparticle preparations 
using double emulsion method, which is frequently used for 
preparation of nanoparticles. However, chitosan, nanoparti- 
cles often have to be hardened by cross-linking with 
potentially toxic agents. Formulations were optimized by 
factorial design. The optimized batch, with optimum physico- 
 
 
 
 
Fig. 7. In vitro cytotoxicity of a RPMI control and octanoyl chitosan and b DMSO control in A549 cells. (n = 3, mean ± SD) 
  
 
 
Table VIII. Stability of OC-Rif NPs at Ambient RT 
 
Sr. no. Time Drug MPS (nm) PDI 
(months) content (%) 
 
 
1 Initial 100 253.43 ± 19.06 0.323 ± 0.059 
2 2 98.03 ± 5.26 261.73 ± 16.37 0.402 ± 0.014 
 
 
n = 3, mean ± SD; MPS—mean particle size, PDI—polydispersity  
index 
 
chemical parameters exhibited good incorporation of rifam- 
picin in the octanoyl chitosan nanoparticles. Electron micros- 
copy revealed spherical particles with smooth surfaces, while 
DSC and XRD studies indicated molecular dispersion of 
rifampicin in the octanoyl chitosan nanoparticles. The sphe- 
ricity and positive surface charge of the octanoyl chitosan 
nanocarriers are expected to increase cell surface afﬁnity and 
uptake of nanocarriers (57). In addition, the mucoadhesive/ 
bioadhesive property of chitosan would potentially increase 
the residence time of the formulations in the lungs, success- 
fully delivered from a jet nebulizer, which might enhance the 
efﬁciency of antibiotic for the treatment of infections. 
Biodegradability and non-cytotoxicity (as determined by 
MTT assay) of this natural polymer suggests its likely safety 
in clinical use. In sum, the results of this study have 
demonstrated the desirable potential of octanoyl chitosan 
and octanoyl chitosan nanoparticles for lung delivery of 
rifampicin. Further evaluations in animals are required to 
further evaluate its utility and potential clinical use. 
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